暴露/反应阻止增效后停药:强迫症患者维持健康的随机临床试验
这项为期24周的双盲随机临床试验纳入137名接受5-羟色胺再摄取抑制剂(SRI)治疗且Y-BOCS≥18分的强迫症成人,EX/RP增效后103人达到健康状态(Y-BOCS≤14分)。101人随机分为减药至安慰剂组(51人)与继续SRI组(50人),24周时减药组Y-BOCS、HDRS、Q-LES-Q-SF均非劣于继续组,但减药组临床恶化率更高(45% vs 24%,P=.04)。
要点
- EX/RP增效达标后减停SRI,24周时症状与生活质量非劣于继续用药。
- 减药组临床恶化率高于继续组(45% vs 24%,P=.04)。
- 作者建议未来研究评估SRI半衰期是否影响临床恶化率。
核心结论
- 在EX/RP增效后达到健康状态的强迫症患者中,减停SRI在24周时平均结局非劣于继续SRI治疗,但减药组临床恶化率更高。
研究设计与样本
- 24周双盲随机临床试验,2013年5月3日至2018年6月25日在美国学术医疗中心开展,纳入137名成人强迫症患者,103人(75.2%)达到健康状态后进入随机分组,101人参与试验(减药组51人,继续组50人)。
主要发现
- 24周时减药组与继续组平均Y-BOCS评分分别为11.47分与11.51分,差值-0.04分,单侧95%CI为-∞至2.09分,低于3.0分非劣效界值。
- 24周时减药组与继续组平均HDRS评分分别为5.69分与4.61分,差值1.08分,单侧95%CI为-∞至2.28分,低于2.5分非劣效界值。
- 24周时减药组与继续组平均Q-LES-Q-SF评分分别为68.01%与70.01%,差值2.00%,单侧95%CI为-∞至6.83,低于7.75非劣效界值。
- 减药组临床恶化率高于继续组(23/51[45%] vs 12/50[24%],P=.04)。
关键数值与推荐
- 研究纳入标准为强迫症病程≥1年、服用SRI≥12周、Y-BOCS评分≥18分,并接受最多25次EX/RP治疗。
- 健康状态定义为Y-BOCS评分≤14分。
- 非劣效检验采用单侧α=.05,Y-BOCS非劣效界值为3.0分,HDRS非劣效界值为2.5分,Q-LES-Q-SF非劣效界值为7.75。
临床怎么用
- 作者认为,经EX/RP增效后达到健康状态的强迫症患者平均可减停SRI,且结局非劣于继续用药,但减药者临床恶化率更高。
- 作者建议未来研究评估SRI半衰期是否改变这些临床恶化率。
局限性
- 原文结论提出未来研究应评估SRI半衰期是否影响临床恶化率,提示半衰期的影响尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Serotonin reuptake inhibitors (SRIs) are the only medications approved for obsessive-compulsive disorder (OCD), yet most patients taking SRIs exhibit significant symptoms. Adding exposure/response prevention (EX/RP) therapy improves symptoms, but it is unknown whether patients maintain wellness after discontinuing SRIs. OBJECTIVE: To assess whether patients with OCD who are taking SRIs and have attained wellness after EX/RP augmentation can discontinue their SRI with noninferior outcomes compared with those who continue their SRI therapy. DESIGN, SETTING, AND PARTICIPANTS: A 24-week, double-blind, randomized clinical trial was performed from May 3, 2013, to June 25, 2018. The trial took place at US academic medical centers. Participants included 137 adults with a principal diagnosis of OCD (≥1 year) who were taking an SRI (≥12 weeks), had at least moderate symptoms (defined as Yale-Brown Obsessive-Compulsive Scale [Y-BOCS] score ≥18 points), and received as many as 25 sessions of EX/RP therapy. Those who attained wellness (Y-BOCS score ≤14 points; 103 patients [75.2%]) were study eligible. Data were analyzed from June 29, 2019, to October 2, 2021. INTERVENTION: Participants were randomly assigned either to receive taper to placebo (taper group) or to continue their SRI (continuation group) and monitored for 24 weeks. MAIN OUTCOME AND MEASURES: The Y-BOCS score (range, 0-40 points) was the primary outcome; the Hamilton Depression Rating Scale (HDRS; range, 0-52 points) and the Quality-of-Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF; range, 0%-100%) scores were secondary outcomes. Outcomes were assessed at 8 time points by independent evaluators who were blinded to randomization. The taper regimen was hypothesized to be noninferior to continuation at 24 weeks using a 1-sided α value of .05. RESULTS: A total of 101 patients (mean [SD] age, 31.0 [11.2] years; 55 women [54.5%]) participated in the trial: 51 patients (50.5%) in the taper group and 50 patients (49.5%) in the continuation group. At 24 weeks, patients in the taper group had noninferior results compared with patients in the continuation group (mean [SD] Y-BOCS score: taper group, 11.47 [6.56] points; continuation group: 11.51 [5.97] points; difference, -0.04 points; 1-sided 95% CI, -∞ to 2.09 points [below the noninferiority margin of 3.0 points]; mean [SD] HDRS score: taper group, 5.69 [3.84] points; continuation group, 4.61 [3.46] points; difference, 1.08 points; 1-sided 95% CI, -∞ to 2.28 points [below the noninferiority margin of 2.5 points]; mean [SD] Q-LES-Q-SF score: taper group, 68.01% [15.28%]; continuation group, 70.01% [15.59%]; difference, 2.00%; 1-sided 95% CI, -∞ to 6.83 [below the noninferiority margin of 7.75]). However, the taper group had higher rates of clinical worsening (23 of 51 [45%] vs 12 of 50 [24%]; P = .04). CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial show that patients with OCD who achieve wellness after EX/RP therapy could, on average, discontinue their SRI with noninferior outcomes compared with those who continued their SRI. Those who tapered the SRI had higher clinical worsening rates. Future research should evaluate if SRI half-life alters these rates. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01686087.
引用
- Foa EB, Simpson HB, Gallagher T, et al. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 35080598. doi:10.1001/jamapsychiatry.2021.3997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。